Literature DB >> 8091684

Stimulation of heterologous protein degradation by the Vpu protein of HIV-1 requires the transmembrane and cytoplasmic domains of CD4.

L Buonocore1, T G Turi, B Crise, J K Rose.   

Abstract

The small membrane protein Vpu of human immunodeficiency virus type 1 stimulates rapid degradation of CD4 molecules that are retained in the endoplasmic reticulum. To analyze the domain(s) of CD4 involved in Vpu-stimulated degradation, we examined degradation of hybrid proteins made between the vesicular stomatitis virus glycoprotein (VSV G) and CD4. Vpu expression stimulated rapid degradation of a hybrid consisting of the extracellular domain of VSV G linked to the transmembrane and cytoplasmic domains of CD4. Analysis of additional hybrids showed that both the cytoplasmic and transmembrane domains of CD4 were required for this Vpu-stimulated degradation. This conclusion is in apparent conflict with a recent study showing that the cytoplasmic domain of CD4 alone is sufficient to cause Vpu-stimulated degradation of a CD8-CD4 hybrid protein. The apparent conflict may be explained by the presence of related sequences or structures in the transmembrane domains of CD4 and CD8 that are involved in binding Vpu directly or that interact with the Vpu-stimulated degradation system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091684     DOI: 10.1006/viro.1994.1560

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

2.  Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus.

Authors:  M J Schnell; L Buonocore; E Boritz; H P Ghosh; R Chernish; J K Rose
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

3.  The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation.

Authors:  S Bour; U Schubert; K Strebel
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

4.  An uncleaved glycosylphosphatidylinositol signal mediates Ca(2+)-sensitive protein degradation.

Authors:  P C Pauly; C Klein
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

5.  Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

Authors:  E Tiganos; X J Yao; J Friborg; N Daniel; E A Cohen
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.

Authors:  U Schubert; L C Antón; I Bacík; J H Cox; S Bour; J R Bennink; M Orlowski; K Strebel; J W Yewdell
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.

Authors:  M Paul; S Mazumder; N Raja; M A Jabbar
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu.

Authors:  Javier G Magadán; Juan S Bonifacino
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

9.  Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps.

Authors:  Javier G Magadán; F Javier Pérez-Victoria; Rachid Sougrat; Yihong Ye; Klaus Strebel; Juan S Bonifacino
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

10.  Inhibition of Nef- and phorbol ester-induced CD4 degradation by macrolide antibiotics.

Authors:  T Luo; S J Anderson; J V Garcia
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.